Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of LP-168 plus LP-108 in mature B-cell malignancies
CTR20261856Phase 2Active
- Sponsor
- Lupeng Pharmaceutical
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rocbrutinib, lacutoclax in mature B-cell neoplasm (MBCN), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), sponsored by Lupeng Pharmaceutical. Started Jul 2026; status: active.
02
Drugs
rocbrutiniblacutoclax
03
Conditions
mature B-cell neoplasm (MBCN)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on CTR20261856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261856.